S. Azhar
University of Rouen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by S. Azhar.
European Neuropsychopharmacology | 2016
Romain Legrand; Nicolas Lucas; Jonathan Breton; S. Azhar; Jean-Claude do Rego; Pierre Déchelotte; Moïse Coëffier; Sergueï O. Fetissov
Stimulation of feeding is necessary for treatment of pathological conditions of chronic malnutrition due to anorexia. Ghrelin, a hunger hormone, is one of the candidate for pharmacological treatments of anorexia, but because of its instability in plasma has limited efficacy. We previously showed that plasmatic IgG protect ghrelin from degradation and that IgG from obese subjects and mice may increase ghrelin׳s orexigenic effect. In this study we tested if ghrelin alone or combined with IgG may improve feeding in chronically food-restricted mice with or without physical activity-based anorexia (ABA) induced by free access to a running wheel. Mice received a single daily intraperitoneal injection of ghrelin (1nM) together or not with total IgG (1nM) from obese ob/ob or lean mice before access to food during 8 days of 3h/day feeding time. We found that both ghrelin and ghrelin combined with IgG from obese, but not lean mice, prevented ABA, however, they were not able to diminish body weight loss. Physical activity was lower during the feeding period and was increased shortly after feeding in mice receiving ghrelin together with IgG from obese mice. In food-restricted mice without ABA, ghrelin treatments did not have significant effects on food intake. Thus, this study supports pharmacological use of ghrelin or ghrelin combined with IgG from obese animals for treatment of anorexia accompanied by elevated physical activity. The utility of combining ghrelin with protective IgG should be further determined in animal models of anorexia with unrestricted access to food.
Proteomics | 2015
Julien Bertrand; Rachel Marion-Letellier; S. Azhar; Philippe Chan; Romain Legrand; A. Goichon; Ibtissem Ghouzali; Moutaz Aziz; David Vaudry; Guillaume Savoye; Pierre Déchelotte; Moïse Coëffier
Ubiquitin proteasome system contributes to the regulation of intestinal inflammatory response as its inhibition is associated with tissue damage improvement. We aimed to evaluate whether glutamine is able to limit inflammation by targeting ubiquitin proteasome system in experimental colitis. Colitis was induced in male rats by intrarectal instillation of 2‐4‐6‐trinitrobenzen sulfonic acid (TNBS) at day 1. From day 2 to day 6, rats daily received either an intrarectal instillation of PBS (TNBS/PBS group) or glutamine (TNBS/Gln). Rats were euthanized at day 7 and colonic samples were taken to evaluate ubiqutinated proteins by proteomic approach combining 2D electrophoresis and immunoblots directed against ubiquitin. Results were then confirmed by evaluating total expression of proteins and mRNA levels. Survival rate, TNFα, and IL‐1β mRNA were improved in TNBS/Gln compared with TNBS/PBS (p < 0.05). Proteasome activities were affected by TNBS but not by glutamine. We identified eight proteins that were less ubiquitinated in TNBS/PBS compared with controls with no effect of glutamine. Four proteins were more ubiquitinated in TNBS/PBS group and restored in TNBS/Gln group. Finally, 12 ubiquitinated proteins were only affected by glutamine. Among proteins affected by glutamine, eight proteins (GFPT1, Gapdh, Pkm2, LDH, Bcat2, ATP5a1, Vdac1, and Vdac2) were involved in metabolic pathways. In conclusion, glutamine may regulate ubiquitination process during intestinal inflammation.
Scientific Reports | 2018
S. Nobis; A. Goichon; N. Achamrah; Charlène Guérin; S. Azhar; Philippe Chan; Aline Morin; Christine Bole-Feysot; Jean Claude do Rego; David Vaudry; Pierre Déchelotte; L. Belmonte; Moïse Coëffier
Restrictive anorexia nervosa is associated with reduced eating and severe body weight loss leading to a cachectic state. Hypothalamus plays a major role in the regulation of food intake and energy homeostasis. In the present study, alterations of hypothalamic proteome and particularly of proteins involved in energy and mitochondrial metabolism have been observed in female activity-based anorexia (ABA) mice that exhibited a reduced food intake and a severe weight loss. In the hypothalamus, mitochondrial dynamic was also modified during ABA with an increase of fission without modification of fusion. In addition, increased dynamin-1, and LC3II/LC3I ratio signed an activation of autophagy while protein synthesis was increased. In conclusion, proteomic analysis revealed an adaptive hypothalamic protein response in ABA female mice with both altered mitochondrial response and activated autophagy.
Cytokine | 2016
Ibtissem Ghouzali; S. Azhar; Christine Bole-Feysot; Philippe Ducrotté; Pierre Déchelotte; Moïse Coëffier
Protease activated receptors (PARs) and the ubiquitin-proteasome system (UPS) regulate inflammatory response in intestinal cells. We aimed to elucidate putative connections between PARs and UPS pathways in intestinal epithelial cells. Caco-2 cells were treated by agonist peptides of PARs and/or IL-1β and/or proteasome inhibitors, bortezomib or MG132. Inflammatory response was evaluated by measuring IL-8 production. Proteasome activities were also evaluated. We showed that PAR-1 and -2 activation increased release of IL-8 compared with vehicle and independently of IL-1β. In contrast, PAR-4 agonist peptide had no effect. Caspase-like and chymotrypsin-like proteasomal activities were increased by PAR-2 activation only in the presence of IL-1β. Interestingly, in polarized Caco-2 cells, the release of IL-8 was predominantly upregulated in the side where PAR-2 agonist peptide was added, apical or basalolateral. In contrast, proteasome activities were only affected when PAR-2 agonist peptide was added in the apical side. Proteasome inhibitors, bortezomib and MG132, enhanced IL-8 production in both sides, apical and basolateral. In conclusion, PAR-2 activation alone did not affect proteasome but needed inflammatory stimulus IL-1β to synergistically increase chymotrypsin-like activity in intestinal epithelial cells. However, proteasome inhibition led to exacerbate inflammatory response induced by PAR-2 activation.
Biochimica et Biophysica Acta | 2017
Ibtissem Ghouzali; Caroline Lemaître; Wafa Bahlouli; S. Azhar; Christine Bole-Feysot; Mathieu Meleine; Philippe Ducrotté; Pierre Déchelotte; Moïse Coëffier
BACKGROUND Intestinal hyperpermeability has been reported in several intestinal and non-intestinal disorders. We aimed to investigate the role of the ubiquitin proteasome system in gut barrier regulation in two mice models: the water avoidance stress model (WAS) and a post-inflammatory model (post-TNBS). METHODS Both models were applied in C57BL/6 male mice (n=7-8/group); Proteasome was targeted by injection of a selective proteasome inhibitor or by using knock-out mice for β2i proteasome subunit. Finally, glutamine supplementation was evaluated. RESULTS In both models (WAS at day 10, post-TNBS at day 28), we observed an increase in proteasome trypsin-like activity and in inducible β2/constitutive β2 subunit protein expression ratio, associated with an increase in intestinal permeability. Moreover, intestinal hyperpermeability was blunted by intraperitoneal injection of selective proteasome inhibitor in WAS and post-TNBS mice. Of note, knock-out mice for the β2i subunit exhibited a significant decrease in intestinal permeability and fecal pellet output during WAS. Glutamine supplementation also improved colonic permeability in both models. CONCLUSIONS In conclusion, the proteasome system is altered in the colonic mucosa of WAS and post-TNBS mice with increased trypsin-like activity. Associated intestinal hyperpermeability was blunted by immunoproteasome inhibition.
Amino Acids | 2014
Julien Bertrand; A. Goichon; Philippe Chan; S. Azhar; Stéphane Lecleire; Nathalie Donnadieu; David Vaudry; Anne-Françoise Cailleux; Pierre Déchelotte; Moı̈se Coëffier
Nutrition | 2016
Marie François; Swapnali Barde; Romain Legrand; Nicolas Lucas; S. Azhar; Mohammed el Dhaybi; Charlène Guérin; Tomas Hökfelt; Pierre Déchelotte; Moïse Coëffier; Sergueï O. Fetissov
Clinical Nutrition | 2016
S. Nobis; A. Goichon; N. Achamrah; Charlène Guérin; S. Azhar; Philippe Chan; J.C. Do Rego; David Vaudry; Pierre Déchelotte; L. Belmonte; M. Coëffier
Nutrition Clinique Et Metabolisme | 2017
Ibtissem Ghouzali; C. Lemaitre; W. Bahlouli; S. Azhar; M. Meleine; Pierre Déchelotte; Philippe Ducrotté; Moı̈se Coëffier
Nutrition Clinique Et Metabolisme | 2017
S. Nobis; A. Goichon; N. Achamrah; Charlène Guérin; S. Azhar; Philippe Chan; J.-C. Do-Rego; David Vaudry; Pierre Déchelotte; L. Belmonte; M. Coëffier